<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157326</url>
  </required_header>
  <id_info>
    <org_study_id>10077</org_study_id>
    <secondary_id>H6D-MC-LVGU</secondary_id>
    <nct_id>NCT00157326</nct_id>
  </id_info>
  <brief_title>Tadalafil in Subjects With Mild to Moderate Hypertension</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICOS Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      Purpose: The primary objective of this study is to evaluate the efficacy and safety of
      tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks
      with mild to moderate hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy measurement of this study is the mean change after 8 weeks of treatment from baseline in cuff seated trough diastolic blood pressure, cuff seated systolic blood pressures and automated blood pressure monitoring</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by evaluating all reported adverse events and changes in clinical laboratory values, ECGs, and vital signs</measure>
  </secondary_outcome>
  <enrollment type="Actual">180</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a documented medical history of hypertension.

          -  Have cuff seated diastolic blood pressure values greater than or equal to 95 and less
             than or equal to 104 mm at study entry

          -  Have a negative serum pregnancy test at the time of enrollment and agree to use two
             medically reliable methods of contraception until study completion, if female is of
             child-bearing potential, between menarche and 1 year post menopause and not surgically
             sterilized.

          -  Are able to comply with study procedures and visits

        Exclusion Criteria:

          -  Have resistant hypertension or systolic hypertension.

          -  Are obese, defined as having body mass index (BMI) greater than or equal to 35.

          -  Are females who are pregnant or breast feeding.

          -  Have a history of severe renal insufficiency or significant thyroid, renal or hepatic
             disease.

          -  Have a glycosylated hemoglobin A1c (HbA1c) greater than or equal to 10% during the
             screening period.

          -  Have significant anemia.

          -  Have a significant or unstable cardiac history such as history of heart attack,
             unstable angina, or stroke within 6 months of study entry, history of angina that was
             treated with long- or short-acting nitrates within 90 days of study entry, history of
             coronary artery bypass graft surgery or cardiac angioplasty within 90 days of study
             entry, history of abnormal heart rhythms such as sick sinus syndrome or 2nd- or
             3rd-degree AV block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia,
             a history of recurrent ventricular tachycardia, or symptomatic bradycardia, a history
             of sudden cardiac arrest.

          -  Have symptomatic heart failure requiring treatment, or significant disease of the
             heart valves.

          -  Have been treated for severe asthma, bronchospasm, or COPD within 3 months of study
             entry.

          -  Have severe peripheral vascular disease.

          -  Have a documented diagnosis of sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>October 23, 2007</last_update_submitted>
  <last_update_submitted_qc>October 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2007</last_update_posted>
  <keyword>High Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

